The economic value of mismatch repair–guided immunotherapy in endometrial cancer: companion testing and patient selection
Mismatch repair (MMR) status has moved from hereditary-cancer screening to a central predictive biomarker for immunotherapy in endometrial cancer. The marked difference in treatment benefit between MMR-deficient/microsatellite instability-high (dMMR/MSI-H) and MMR-proficient/microsatellite-stable (pMMR/MSS) tumors crea...